Bayesian indirect and mixed treatment comparisons across longitudinal time points

Statistics in Medicine

Volumn 32, Issue 15, 2013, Pages 2613-2628

  Ding, Ying ^a   Fu, Haoda ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bayesian methods; BEST; Comparative effectiveness research; Indirect comparison; ITP model; Meta analysis

Indexed keywords

ARTICLE; BAYES THEOREM; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MATHEMATICAL MODEL; PREDICTION; PROBABILITY; PROCESS MODEL; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

BAYES THEOREM; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879096038     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5688     Document Type: Article

References (27)

1. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997; 50(6):683-691.
2. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002; 21(16):2313-2324.
3. Cooper HM, Hedges LV, Valentine JC. The Handbook of Research Synthesis and Meta-Analysis, (2nd edn). Russell Sage Foundation: New York, 2009.
4. NICE. NICE evidence synthesis technical support documents, 2012. Available from: http://www.nicedsu.org.uk/Evidence-Synthesis-TSD-series(2391675).htm [Accessed date December 04, 2012].
5. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011; 14(4):417-428.
6. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14:429-437.
7. Eddy DM, Hasselblad V, Shachter R. An introduction to a Bayesian method for meta-analysis: the confidence profile method. Medical Decision Making 1990; 10(1):15-23.
8. Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Statistics in Medicine 2003; 22(19):2995-3016.
9. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004; 23(20):3105-3124.
10. Lu G, Ades AE, Sutton AJ, Cooper NJ, BriggS AH, Caldwell DM. Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine 2007; 26(20):3681-3699.
11. Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Medical Research Methodology 2011; 11:61.
12. Fu H, Manner D. Bayesian adaptive dose-finding studies with delayed responses. Journal of Biopharmaceutical Statistics 2010; 20(5):1055-1070.
13. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Statistics in Medicine 1995; 14(24):2685-2699.
14. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006; 101(474):447-459.
15. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health Care Evaluation. Statistics in Practice. Wiley: Chichester; Hoboken, NJ, 2004.
16. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27(11):2628-2635.
17. Bymaster FP, Beedle EE, Findlay J, Gallagher PT, Krushinski JH, Mitchell S, Robertson DW, Thompson DC, Wallace L, Wong DT. Duloxetine (cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorganic and Medicinal Chemistry Letters 2003; 13(24):4477-4480.
18. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S. A randomized trial of a low-carbohydrate diet for obesity. New England Journal of Medicine 2003; 348(21):2082-2090.
19. Shargel L, Wu-Pong S, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. (5th edn). Appleton & Lange Reviews/McGraw-Hill, Medical Pub. Division: New York, 2005.
20. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. (3rd edn). Williams & Wilkins: Baltimore, 1995.
21. Li W, Fu H. Bayesian optimal adaptive designs for delayed-response dose-finding studies. Journal of Biopharmaceutical Statistics 2011; 21(5):888-901.
22. Sutton AJ, Abrams KR, Jones D, Sheldon T, Song F. Methods for Meta-Analysis in Medical Research. Wiley Series in Probability and Mathematical Statistics. John Wiley & Sons Ltd: Chichester; New York, 2000.
23. Whitehead A. Meta-Analysis of Controlled Clinical Trials. Statistics in Practice. John Wiley & Sons: Chichester; New York, 2002.
24. Gelman A, Hill J. Data Analysis Using Regression and Multilevel/Hierarchical Models. Analytical Methods for Social Research. Cambridge University Press: Cambridge; New York, 2007.
25. Shao J. Mathematical Statistics. (2nd edn), Springer Texts in Statistics. Springer: New York, 2003.
26. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. (2nd edn), Chapman & Hall/CRC Biostatistics Series 20. Chapman & Hall/CRC: Boca Raton, 2008.
27. Chuang-Stein C. Sample size and the probability of a successful trial. Pharmaceutical Statistics 2006; 5(4):305-309.